Log in

Icon Stock Price, Forecast & Analysis (NASDAQ:ICLR)

$152.42
+2.12 (+1.41 %)
(As of 11/15/2019 03:09 AM ET)
Today's Range
$149.34
Now: $152.42
$152.69
50-Day Range
$140.06
MA: $146.22
$151.85
52-Week Range
$118.10
Now: $152.42
$165.13
Volume173,900 shs
Average Volume264,727 shs
Market Capitalization$8.23 billion
P/E Ratio24.23
Dividend YieldN/A
Beta0.69
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICLR
CUSIPN/A
Phone353-1291-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.60 billion
Cash Flow$7.93 per share
Book Value$25.09 per share

Profitability

Net Income$322.66 million

Miscellaneous

Employees13,670
Market Cap$8.23 billion
Next Earnings Date2/19/2020 (Estimated)
OptionableOptionable

Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.


Icon (NASDAQ:ICLR) Frequently Asked Questions

What is Icon's stock symbol?

Icon trades on the NASDAQ under the ticker symbol "ICLR."

How were Icon's earnings last quarter?

Icon Plc (NASDAQ:ICLR) posted its quarterly earnings results on Wednesday, October, 23rd. The medical research company reported $1.74 earnings per share for the quarter, meeting analysts' consensus estimates of $1.74. The medical research company had revenue of $710.40 million for the quarter, compared to the consensus estimate of $709.75 million. Icon had a net margin of 13.16% and a return on equity of 25.30%. The firm's quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the company posted $1.54 EPS. View Icon's Earnings History.

When is Icon's next earnings date?

Icon is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Icon.

What guidance has Icon issued on next quarter's earnings?

Icon issued an update on its FY19 earnings guidance on Wednesday, October, 23rd. The company provided earnings per share guidance of $6.81-6.95 for the period, compared to the Thomson Reuters consensus estimate of $6.88. The company issued revenue guidance of $2.79-2.83 billion, compared to the consensus revenue estimate of $2.81 billion.

What price target have analysts set for ICLR?

8 analysts have issued twelve-month price targets for Icon's shares. Their forecasts range from $154.00 to $170.00. On average, they expect Icon's share price to reach $162.57 in the next twelve months. This suggests a possible upside of 6.7% from the stock's current price. View Analyst Price Targets for Icon.

What is the consensus analysts' recommendation for Icon?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Icon.

Has Icon been receiving favorable news coverage?

News stories about ICLR stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Icon earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Icon.

Are investors shorting Icon?

Icon saw a increase in short interest in October. As of October 31st, there was short interest totalling 862,400 shares, an increase of 34.4% from the September 30th total of 641,500 shares. Based on an average daily volume of 227,600 shares, the days-to-cover ratio is presently 3.8 days. Approximately 1.6% of the company's shares are sold short. View Icon's Current Options Chain.

Who are some of Icon's key competitors?

What other stocks do shareholders of Icon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Icon investors own include Pfizer (PFE), Gilead Sciences (GILD), CVS Health (CVS), Mastercard (MA), Procter & Gamble (PG), Post (POST), Visa (V), Johnson & Johnson (JNJ), Amgen (AMGN) and Euronet Worldwide (EEFT).

Who are Icon's key executives?

Icon's management team includes the folowing people:
  • Dr. Steven A. Cutler, CEO & Director (Age 59)
  • Mr. Brendan Brennan, Chief Financial Officer (Age 40)
  • Jonathan Curtain, VP of Corp. Fin. & Investor Relations
  • Mr. Thomas O'Leary, Chief Information Officer
  • Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 44)

Who are Icon's major shareholders?

Icon's stock is owned by a number of of institutional and retail investors. Top institutional investors include WCM Investment Management LLC (6.66%), Comgest Global Investors S.A.S. (2.83%), Massachusetts Financial Services Co. MA (2.58%), Stephens Investment Management Group LLC (1.05%), SPF Beheer BV (0.96%) and Peregrine Capital Management LLC (0.43%).

Which major investors are selling Icon stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including Renaissance Group LLC, Peregrine Capital Management LLC, Stephens Investment Management Group LLC, Russell Investments Group Ltd., Systematic Financial Management LP, RBA Wealth Management LLC, GW&K Investment Management LLC and Dean Capital Investments Management LLC.

Which major investors are buying Icon stock?

ICLR stock was purchased by a variety of institutional investors in the last quarter, including Comgest Global Investors S.A.S., SPF Beheer BV, WCM Investment Management LLC, Massachusetts Financial Services Co. MA, California Public Employees Retirement System, Meritage Portfolio Management, Fisher Asset Management LLC and CIBC Private Wealth Group LLC.

How do I buy shares of Icon?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Icon's stock price today?

One share of ICLR stock can currently be purchased for approximately $152.42.

How big of a company is Icon?

Icon has a market capitalization of $8.23 billion and generates $2.60 billion in revenue each year. The medical research company earns $322.66 million in net income (profit) each year or $6.29 on an earnings per share basis. Icon employs 13,670 workers across the globe.View Additional Information About Icon.

What is Icon's official website?

The official website for Icon is http://www.iconplc.com/.

How can I contact Icon?

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.


MarketBeat Community Rating for Icon (NASDAQ ICLR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  498 (Vote Outperform)
Underperform Votes:  431 (Vote Underperform)
Total Votes:  929
MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel